Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through β-lactam-enhancer-mechanism-based cefepime/zidebactam.
Hujer AM, Marshall SH, Mack AR, Hujer KM, Bakthavatchalam YD, Umarkar K, Palwe SR, Takalkar S, Joshi PR, Shrivastava R, Periasamy H, Bhagwat SS, Patel MV, Veeraraghavan B, Bonomo RA. Hujer AM, et al. Among authors: patel mv. mBio. 2023 Oct 27;14(6):e0111823. doi: 10.1128/mbio.01118-23. Online ahead of print. mBio. 2023. PMID: 37889005 Free PMC article.
Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3.
Bhagwat SS, Hariharan P, Joshi PR, Palwe SR, Shrivastava R, Patel MV, Devanga Ragupathi NK, Bakthavatchalam YD, Ramesh MS, Soman R, Veeraraghavan B. Bhagwat SS, et al. Among authors: patel mv. J Antimicrob Chemother. 2020 Dec 1;75(12):3563-3567. doi: 10.1093/jac/dkaa353. J Antimicrob Chemother. 2020. PMID: 32772098
WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.
Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonomo RA, Oliver A. Moya B, et al. Antimicrob Agents Chemother. 2017 May 24;61(6):e02529-16. doi: 10.1128/AAC.02529-16. Print 2017 Jun. Antimicrob Agents Chemother. 2017. PMID: 28289035 Free PMC article.
Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234.
Papp-Wallace KM, Nguyen NQ, Jacobs MR, Bethel CR, Barnes MD, Kumar V, Bajaksouzian S, Rudin SD, Rather PN, Bhavsar S, Ravikumar T, Deshpande PK, Patil V, Yeole R, Bhagwat SS, Patel MV, van den Akker F, Bonomo RA. Papp-Wallace KM, et al. Among authors: patel mv. J Med Chem. 2018 May 10;61(9):4067-4086. doi: 10.1021/acs.jmedchem.8b00091. Epub 2018 Apr 20. J Med Chem. 2018. PMID: 29627985 Free PMC article.
In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae.
Moya B, Barcelo IM, Cabot G, Torrens G, Palwe S, Joshi P, Umarkar K, Takalkar S, Periasamy H, Bhagwat S, Patel M, Bou G, Oliver A. Moya B, et al. Antimicrob Agents Chemother. 2019 Apr 25;63(5):e00128-19. doi: 10.1128/AAC.00128-19. Print 2019 May. Antimicrob Agents Chemother. 2019. PMID: 30782985 Free PMC article.
In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals.
Bhagwat SS, Legakis NJ, Skalidis T, Loannidis A, Goumenopoulos C, Joshi PR, Shrivastava R, Palwe SR, Periasamy H, Patel MV, Chatzipanagiotou S; Hellenic Cefepime/Zidebactam Study Group. Bhagwat SS, et al. Among authors: patel mv. Diagn Microbiol Infect Dis. 2021 Jul;100(3):115327. doi: 10.1016/j.diagmicrobio.2021.115327. Epub 2021 Jan 30. Diagn Microbiol Infect Dis. 2021. PMID: 33744624
179 results